Semliki forest virus as a vector: pros and cons for its use in biopharmaceuticals production

The number of biopharmaceuticals for medical and veterinarian use produced in mammalian cells is increasing year after year. All of them are obtained by stable recombinant cell lines. However, it is recognized that transient gene expression produces high level expression in a short time. In that sen...

Full description

Saved in:
Bibliographic Details
Published inBrazilian Archives of Biology and Technology Vol. 56; no. 5; pp. 859 - 866
Main Authors Núñez, Eutimio Gustavo Fernández, Jorge, Soraia Attie Calil, Astray, Renato Mancini, Rezende, Alexandre Gonçalves de, Costa, Bruno Labate Vale da, Monteiro, Daniella Cristina Ventini, Pereira, Carlos Augusto, Tonso, Aldo
Format Journal Article
LanguageEnglish
Published Instituto de Tecnologia do Paraná (Tecpar) 01.10.2013
Subjects
BHK-21
Large-scale bioprocesses
Mammalian cells
Recombinant proteins
SFV
Transient expression
Online AccessGet full text

Cover

More Information
Summary:The number of biopharmaceuticals for medical and veterinarian use produced in mammalian cells is increasing year after year. All of them are obtained by stable recombinant cell lines. However, it is recognized that transient gene expression produces high level expression in a short time. In that sense, viral vectors have been extensively used for producing recombinant proteins on lab-scale. Among them, Semliki Forest virus is commonly employed for this purpose. This review discusses the main aspects related to the use of Semliki Forest virus technology as well as its advantages and drawbacks which limit currently its utilization in biopharmaceutical industry on large-scale.
ISSN:1516-8913
1678-4324
1516-8913
DOI:10.1590/S1516-89132013000500018